Race Oncology is pleased to release a detailed commercial assessment of the market potential for Zantrene® as a cardio-protective agent or dual cardio-protective + anti-cancer in breast, endometrial and ovarian cancers.
Key points from the research include:

• Independent analysis suggests use case for Zantrene in nearly the entire identified target patient population as a cardio-protective oncology drug if anticancer benefits are demonstrated
• If anti-cancer efficacy is demonstrated, sales for Zantrene could represent an overall peak commercial value of ~$1.7B USD in breast cancer alone within the US (~$3.4B USD globally)
• Revenue may extend to $5-8B USD annually if expansion is achieved into additional identified cancer indications and further approvals are obtained in ex US markets.

CEO and Managing Director, Damian Clarke-Bruce commented, “It is pleasing to now be able to share this complete research report to further illustrate what the cardio-protection market potential may look like. This has been defined with three unique clinical scenarios, where Zantrene has demonstrated pre-clinical and historically, early phase therapeutic outcomes. Our thanks go to the Triangle team for taking the time to provide the additional colour on this important piece of research.

It is clear that anthracycline-associated cardiotoxicity remains a major concern for oncologists, and one which can impact the physician’s approach to dosing, sequencing and overall treatment regime. We hope that our clinical program will be able to provide a therapeutic option to enable optimal treatment outcomes for cancer patients globally, receiving anthracycline therapy.”

Video resource available

In addition to the presentation, a video is available to investors, where the Triangle Insights research team provides further context to the slides. The video is available for viewing below.